Liraglutide (Victoza) for type 2 diabetes

Medical Letter on Drugs and Therapeutics

Volumn 52, Issue 1335, 2010, Pages 25-27

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BYDUREON; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG COST; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DYSPEPSIA; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; SIDE EFFECT; THYROID C CELL HYPERPLASIA; THYROID HYPERPLASIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON;

EID: 77950799867     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47:45.
2. DJ Drucker et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008; 372:1240.
3. A Garber et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373:473.
4. M Nauck et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. LEAD-2 Study Group. Diabetes Care 2009; 32:84.
5. M Marre et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). LEAD-1 SU Study Group. Diabet Med 2009; 26:268.
6. D Russell-Jones et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU); a randomised controlled trial. Liraglutide effect and action in diabetes 5 (LEAD-5) met+SU Study Group. Diabetologia 2009; 52:2046.
7. B Zinman et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Med+TZD). LEAD-4 Study Group. Diabetes Care 2009; 32:1224.
8. JB Buse et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). LEAD-6 Study Group. Lancet 2009; 374:39. Epub 2009 Jun 8.